The association between chemerin expression in breast cancer cells and aggressiveness

Breast cancer (BC), the most prevalent cancer amongst women globally, exhibits a complex relationship with obesity and its associated factors. Chemerin, an adipokine linked to both inflammatory and metabolic processes, has emerged as a potential player in tumor development and progression. This study delves into the potential role of chemerin in breast cancer by analyzing its expression patterns in tumor cells, fibroblasts, and adipocytes alongside corresponding clinico-pathological parameters.

Encompassing 77 patients with invasive ductal carcinoma, the study revealed an interesting interplay between chemerin and disease characteristics.

While chemerin expression itself did not associate with established markers like BC stage, oestrogen receptor, or progesterone receptor status, its presence is elevated in patients with lymph node metastasis. Despite these insightful findings, the study acknowledges limitations inherent to its design. The absence of a healthy control group necessitates further controlled studies to solidify the observed associations. Additionally, external factors like diet and exercise, known to influence chemerin levels, were not accounted for, requiring more comprehensive patient history and examination data in future investigations.

While chemerin expression did not correlate with traditional BC markers, its apparent associations with lymph node metastasis, c-ERB2 expression, and involvement within the tumour microenvironment warrant further exploration. This study paves the way for future research to elucidate the precise role of chemerin in BC development and progression, potentially paving the path for the development of novel diagnostic and prognostic tools.